Research Article
Integrative Bioinformatics Analysis Identifies DDX60 as a Potential Biomarker for Systemic Lupus Erythematosus
Table 1
Classification of SLE patients according to four clinical assessments.
| | Clinical assessments | Classification |
| | SLEDAI | 0-4, inactive; 5-9, mild activity; 10-14, moderate activity; ≥15, severe activity | | Anti-dsDNA | <30 IU was defined as the “negative” group and ≥30 IU as the “positive” group | | C3 | <0.9 g/L was defined as the “low” group and ≥0.9 g/L as the “normal or high” group | | C4 | <0.1 g/L was defined as the “low” group and ≥0.1 g/L as the “normal or high” group |
|
|
SLEDAI: systemic lupus erythematosus disease activity index; anti-dsDNA: anti-double-stranded DNA; C3: complement component C3; C4: complement component C4.
|
